BRPI0914192A2 - distribuição transdérmica de fármaco usando um osmólito e agente vasoativo - Google Patents

distribuição transdérmica de fármaco usando um osmólito e agente vasoativo

Info

Publication number
BRPI0914192A2
BRPI0914192A2 BRPI0914192A BRPI0914192A BRPI0914192A2 BR PI0914192 A2 BRPI0914192 A2 BR PI0914192A2 BR PI0914192 A BRPI0914192 A BR PI0914192A BR PI0914192 A BRPI0914192 A BR PI0914192A BR PI0914192 A2 BRPI0914192 A2 BR PI0914192A2
Authority
BR
Brazil
Prior art keywords
osmolyte
drug delivery
transdermal drug
vasoactive agent
vasoactive
Prior art date
Application number
BRPI0914192A
Other languages
English (en)
Inventor
John J Masiz
Kanu Patel
Stephen G Carter
Zhen Zhu
Original Assignee
Biochemics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemics Inc filed Critical Biochemics Inc
Publication of BRPI0914192A2 publication Critical patent/BRPI0914192A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0914192A 2008-09-22 2009-09-22 distribuição transdérmica de fármaco usando um osmólito e agente vasoativo BRPI0914192A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9912908P 2008-09-22 2008-09-22
PCT/US2009/057916 WO2010034019A1 (en) 2008-09-22 2009-09-22 Transdermal drug delivery using an osmolyte and vasoactive agent

Publications (1)

Publication Number Publication Date
BRPI0914192A2 true BRPI0914192A2 (pt) 2015-11-03

Family

ID=41449932

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914192A BRPI0914192A2 (pt) 2008-09-22 2009-09-22 distribuição transdérmica de fármaco usando um osmólito e agente vasoativo

Country Status (7)

Country Link
US (3) US9566256B2 (pt)
EP (1) EP2207536A1 (pt)
BR (1) BRPI0914192A2 (pt)
CA (1) CA2702604C (pt)
CO (1) CO6361907A2 (pt)
MX (2) MX349176B (pt)
WO (1) WO2010034019A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349176B (es) 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
US9278233B2 (en) * 2008-12-04 2016-03-08 Biochemics, Inc. Methods and compositions for tattoo removal
KR20130058012A (ko) 2010-04-28 2013-06-03 킴벌리-클라크 월드와이드, 인크. 사출 성형된 마이크로니들 어레이 및 마이크로니들 어레이의 형성 방법
EP2563455A4 (en) 2010-04-28 2014-02-19 Kimberly Clark Co METHOD FOR INCREASING THE PERMEABILITY OF AN EPITHELIAL BARRIER
MX345837B (es) 2010-04-28 2017-02-16 Kimberly-Clark Worldwide Incorporated Dispositivo para la entrega de un medicamento para la artritis reumatoide.
WO2011135531A2 (en) 2010-04-28 2011-11-03 Kimberly-Clark Worldwide, Inc. MEDICAL DEVICES FOR DELIVERY OF siRNA
US8512770B2 (en) 2010-08-04 2013-08-20 Dominion Resources Unlimited, Llc Skin penetration composition
MX343262B (es) 2011-10-27 2016-10-28 Kimberly Clark Co Administración transdérmica de agentes bioactivos de alta viscosidad.
JP6535464B2 (ja) 2011-10-27 2019-06-26 ソレント・セラピューティクス・インコーポレイテッド 生理活性薬剤の送達のための移植可能な装置
US20170246439A9 (en) 2011-10-27 2017-08-31 Kimberly-Clark Worldwide, Inc. Increased Bioavailability of Transdermally Delivered Agents
CN103957998B (zh) 2011-12-06 2018-06-12 荷兰联合利华有限公司 皮肤抗老化组合物
US9587169B2 (en) * 2012-01-12 2017-03-07 Courtney Gene Rogers Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing
CA2906765A1 (en) 2013-03-15 2014-09-18 Biochemics, Inc. Topical formulations and methods for drug delivery
WO2015066699A1 (en) * 2013-11-04 2015-05-07 ROGERS, Courtney, Gene Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing
WO2018213071A1 (en) 2017-05-15 2018-11-22 Biochemics, Inc. Transdermally-delivered combination drug therapy for pain
PL3709968T3 (pl) * 2017-11-14 2024-02-19 Profem Gmbh Emulsje do leczenia infekcji pochwy
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
IT201800003902A1 (it) * 2018-03-23 2019-09-23 Sebastiano Turrini Unguento a base di ibuprofene racemico transedermico
CA3112808A1 (en) 2018-09-27 2020-04-02 BioPhysics Pharma, Inc. Transdermal drug delivery system
US12246098B2 (en) 2018-09-27 2025-03-11 BioPhysics Pharma, Inc. Trans-epithelial membrane drug delivery system
BR112022016439A2 (pt) * 2020-02-20 2022-10-04 North Atlantic Holdings LLC Sistema de aplicação transmucosal de fármaco

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440777A (en) 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4933184A (en) 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4758599A (en) 1986-06-04 1988-07-19 American Cyanamid Company Clear, hydroalcoholic aftershave lotion which moisturizes, conditions, and prevents irritation
US4830856A (en) 1987-01-27 1989-05-16 Peppers James M Chelation product
US4859704A (en) 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
GB8905815D0 (en) 1989-03-14 1989-04-26 Beecham Group Plc Medicament
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US5093133A (en) 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
EP0584108B1 (en) 1991-05-13 2000-08-16 The Boots Company PLC Pharmaceutical composition comprising ibuprofen salt
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5451704A (en) 1992-12-23 1995-09-19 Mobil Oil Corporation Alpha-olefin oligomerization using supported metal halide catalysts
US5451407A (en) * 1993-06-21 1995-09-19 Alza Corporation Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5645854A (en) 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
US5460821A (en) 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
IT1265001B1 (it) 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5527530A (en) 1994-07-08 1996-06-18 The Procter & Gamble Company Alcoholic moisturizing after shave lotion
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US6228873B1 (en) * 1994-12-09 2001-05-08 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US6527716B1 (en) 1997-12-30 2003-03-04 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
US6321909B1 (en) 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
US5980882A (en) 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6248763B1 (en) * 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6207713B1 (en) 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US5895658A (en) 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US5922332A (en) 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US6486206B1 (en) 1997-09-29 2002-11-26 Cprx Inc. Mechanical and pharmacologic therapies to treat cardiac arrest
US6306130B1 (en) 1998-04-07 2001-10-23 The General Hospital Corporation Apparatus and methods for removing blood vessels
US6477410B1 (en) 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
JP4698843B2 (ja) * 1999-05-17 2011-06-08 エーザイ インコーポレイテッド 生体活性剤の改良された細胞取り込み
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
US7105172B1 (en) 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
FR2808191B1 (fr) 2000-04-28 2004-03-05 Oreal Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations
AU2001290552A1 (en) * 2000-09-15 2002-03-26 Medical Merchandising, Inc. Pain reliever and method of use
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US6936589B2 (en) * 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
US20030091659A1 (en) 2001-11-09 2003-05-15 Avon Products, Inc. Topical composition having undifferentiated plant seed cells and method for using same
US20030104043A1 (en) 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US7041677B2 (en) 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
JP2005518823A (ja) * 2002-03-08 2005-06-30 マクギル・ユニバーシテイ 未成熟ヒト卵母細胞の体外成熟
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
CN101862292A (zh) 2002-06-17 2010-10-20 塔罗制药美国公司 布洛芬混悬剂
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US6927206B2 (en) 2003-06-06 2005-08-09 Procyte Corporation Compositions and methods for treatment of rosacea
US20080112909A1 (en) 2003-06-24 2008-05-15 Ppg Industries Ohio, Inc. Compositions for providing color to animate objects and related methods
US7375139B2 (en) * 2003-08-18 2008-05-20 Aldred Katherine M Transdermal method and apparatus
CA2540742A1 (en) 2003-09-30 2005-04-14 Terry Hicks Compositions and methods for treating burns
ITMI20032322A1 (it) * 2003-11-27 2005-05-28 Carlo Ghisalberti Dispositivo atossico per facilitare la venipuntura.
WO2005091891A2 (en) 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
EP1588697A1 (en) 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
JP2007532697A (ja) 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US20050256204A1 (en) 2004-05-11 2005-11-17 Bitter Patrick H Sr Topical phenyl-epinephrine Rosacea treatment
GB0413635D0 (en) 2004-06-18 2004-07-21 Smith & Nephew Ultrasonic treatment
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
US20060062836A1 (en) * 2004-09-21 2006-03-23 Carter Stephen G Methods of device-assisted drug delivery
US20060217690A1 (en) 2005-03-22 2006-09-28 Bastin Norman J Method for treating various dermatological and muscular conditions using electromagnetic radiation
WO2006104660A1 (en) 2005-03-24 2006-10-05 Avery Dennison Corporation Occlusive wound dressing useful in tattoo removal
DE102005055275A1 (de) * 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
US20070166252A1 (en) 2005-12-30 2007-07-19 Judy Hattendorf Method of treating skin requiring tattoo removal
JPWO2007086395A1 (ja) 2006-01-24 2009-06-18 財団法人浜松科学技術研究振興会 光線力学的療法用キット
US20070178121A1 (en) 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US20090053290A1 (en) 2006-03-08 2009-02-26 Sand Bruce J Transdermal drug delivery compositions and topical compositions for application on the skin
WO2007143002A2 (en) * 2006-05-31 2007-12-13 Interhealth Nutraceuticals, Inc. Nutraceutical treatments for diabetic and non-diabetic wound healing
GB2458228B (en) 2006-10-12 2011-02-23 Rohto Pharma External preparation for skin
KR101069502B1 (ko) 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
WO2008109124A1 (en) 2007-03-06 2008-09-12 Novalar Pharmaceuticals, Inc. Use of nitroglycerin to reverse local anesthesia
JP2010524432A (ja) * 2007-03-19 2010-07-22 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性のバイオマーカーおよびその使用方法
US8354116B2 (en) 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US20090123570A1 (en) * 2007-11-09 2009-05-14 Warner W Randolph Composition and method for treating sore throat
WO2009094473A1 (en) * 2008-01-22 2009-07-30 Biochemics, Inc. Methods and compositions for topical treatment of medical conditions including wounds and inflammation
WO2009111075A2 (en) 2008-03-07 2009-09-11 Frank Pellegrini Ultra bright led induced tattoo removal
US8367122B2 (en) 2008-06-11 2013-02-05 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
CA2749941C (en) 2008-09-10 2018-04-24 Biochemics, Inc. Ibuprofen for topical administration
MX349176B (es) * 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
US9278233B2 (en) 2008-12-04 2016-03-08 Biochemics, Inc. Methods and compositions for tattoo removal

Also Published As

Publication number Publication date
MX2010004169A (es) 2010-10-05
WO2010034019A1 (en) 2010-03-25
CA2702604A1 (en) 2010-03-25
US20100076035A1 (en) 2010-03-25
CA2702604C (en) 2013-12-03
US9566256B2 (en) 2017-02-14
US10751309B2 (en) 2020-08-25
CO6361907A2 (es) 2012-01-20
US10537536B2 (en) 2020-01-21
MX386614B (es) 2025-03-19
US20160128957A1 (en) 2016-05-12
MX349176B (es) 2017-07-14
WO2010034019A4 (en) 2010-05-20
US20160129116A1 (en) 2016-05-12
EP2207536A1 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
IL283459A (en) Novel lipids and compositions for the delivery of therapeutics
BRPI1014139A2 (pt) sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo.
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
BRPI0917358A2 (pt) formulação farmacêutica de liberação controlada e método.
EP2104525A4 (en) HYPODERMIC RESERVOIR AND APPARATUS FOR DRUG DELIVERY
DK2692341T3 (da) Misbrugs-resistent lægemiddelformulering
BRPI0818673A2 (pt) terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2
HRP20170929T1 (hr) Farmaceutski pripravci i odgovarajući postupci za isporuku
DK2231254T3 (da) Implanterbar lægemiddelafgivelsesindretning
BRPI0916150A2 (pt) ''método de infusão intradérmica e dispositivo de aplicação de medicamento''
DK2296732T3 (da) Medikamentafgivelsesindretning
DK2310001T3 (da) Transdermal estradiol-indretning og -indgivelse
ATE531410T1 (de) Arzneimittelabgabevorrichtung
BR112013010102A2 (pt) microagulha, arranjo de microagulhas, dispositivo de microagulhas, e, método para administrar um agente medicinal
BRPI0913214A2 (pt) sistema de fornecimento de drogas transdérmico estabilizado
EP2313122A4 (en) MEDICAL ACTIVE COMPOSITION DEVICE
BRPI0920191A2 (pt) dispositivo para administração de fármaco e método de fabricação de um dispositivo de administração de fármaco
EP3323405C0 (en) SYSTEM AND METHOD FOR DISPENSING MEDICATION
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
IL212767A0 (en) Device and method for drug delivery
BRPI0810899A2 (pt) Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
DK2381988T3 (da) Medikamentadministrationsanordning
EP2398459A4 (en) TRANSDERMAL RELEASE OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE
DK2281576T3 (da) Aktiv målsøgende polymermicelle med deri indkapslet medikament samt medicinsk sammensætning
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.